Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21052171 | 0.84 | NPC1 (0.36) | KDM4EPOLBFFAR4FFAR1NPC1 | |
| SCHEMBL21052172 | 0.84 | NPC1 (0.36) | KDM4EPOLBFFAR4FFAR1NPC1 | |
| SCHEMBL21098674 | 0.84 | NPC1 (0.36) | KDM4EPOLBFFAR4FFAR1NPC1 | |
| SCHEMBL21099222 | 0.81 | FFAR4 (0.40) | KDM4EPOLBFFAR4FFAR1RXRA | |
| SCHEMBL21098745 | 0.78 | FFAR4 (0.35) | FFAR4FFAR1PDK2NPC1RAB9A | |
| SCHEMBL21052032 | 0.78 | FFAR4 (0.35) | FFAR4FFAR1PDK2NPC1RAB9A | |
| SCHEMBL21098676 | 0.76 | FFAR4 (0.41) | FFAR4FFAR1PDK2 | |
| SCHEMBL21099243 | 0.72 | KDM4E (0.37) | KDM4EPOLB | |
| SCHEMBL21098681 | 0.70 | RXRA (0.41) | KDM4EPOLBFFAR4RXRARXRB | |
| SCHEMBL21098668 | 0.70 | PPARD (0.40) | KDM4EPOLBFFAR4FFAR1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019109188-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-06-13 | — | — | WO | disclosed |